


BG-12 MS
Clinical Development Team

Subject: Minutes from BG-12 MS CDT meeting on 19 July 2006

Date: July 19, 2006

From: [REDACTED]

Attendees: Kate Dawson, Tammy Sarnelli, [REDACTED]
Ratna Lingamaneni, [REDACTED]



2	EOP2 Meeting Package	<ul style="list-style-type: none">• EOP2 meeting is scheduled for Aug 30th.• Revised EOP2 timeline:<ul style="list-style-type: none">○ VP review July 21-24○ Comments incorporated July 25-26○ Content final July 26○ Publishing July 27-28○ Submit July 28th
3	Investigator Brochure	<ul style="list-style-type: none">• QTo study requires final IB and PSP by Aug 18th in order to keep revised dosing schedule (first group dosed Sept 8th). Can we meet this timeline?<ul style="list-style-type: none">○ [REDACTED] will work off-line to developed proposed IB/PSP timeline and distributed to team. Goal is that following completion of EOP2 package, will begin work on IB/PSP July 24th.• Is Aug 18th Final IB sufficient time for EU to develop IMPD for Ph 3 submission?<ul style="list-style-type: none">○ [REDACTED] will distribute timeline to [REDACTED] and obtain input if this will meet IMPD development timeline.



